Brain inflammation drives numerous neurodegenerative conditions, yet targeting the root cellular mechanisms has remained elusive. A promising pathway now emerges through mitochondrial quality control—the cellular process that removes damaged powerhouses before they trigger inflammatory cascades. The synthetic compound ADT-OH demonstrates dual protective effects in brain immune cells called microglia. It enhances mitophagy, the selective removal of damaged mitochondria, while simultaneously blocking the cGAS-STING pathway that detects leaked mitochondrial DNA as a danger signal. This interference prevents the inflammatory response that would normally follow mitochondrial damage. The mechanism represents a sophisticated cellular housekeeping system where healthy mitochondria are preserved and damaged ones are eliminated before they can release their contents into the cell interior. When mitochondrial DNA escapes into the cytoplasm, it mimics viral infection, triggering the cGAS-STING immune sensing pathway that leads to neuroinflammation. This research advances our understanding of how cellular energy factories contribute to brain aging and disease. The ability to pharmacologically enhance mitochondrial cleanup while dampening inflammatory signaling offers potential therapeutic directions for conditions where brain inflammation accelerates cognitive decline. However, this appears to be early-stage mechanistic research, likely conducted in laboratory models rather than human trials. The translational potential remains to be established through clinical validation, dosing studies, and safety assessments in human populations before any practical applications emerge.